Reported net sales of $982.9 million, an 11% increase compared to $887.3 million in Q1 2025. Core sales remained flat, as volume growth in Beauty and Closures was offset by lower Pharma emergency medicine sales and lower material cost pass-throughs. Net income attributable to AptarGroup was $72.7 million, down from $78.8 million in the prior year period. Diluted earnings per share (EPS) were $1.12, compared to $1.17 in Q1 2025. Adjusted EBITDA margin for the quarter was 19.2%, down from 20.7% in Q1 2025.